BETAGAN has been shown to be effective in lowering intraocular pressure and may be used in patients with chronic open-angle glaucoma or ocular hypertension.

The recommended starting dose is one to two drops of BETAGAN 0.5% in the affected eye(s) once a day. Typical dosing with BETAGAN 0.25% is one to two drops twice daily. In patients with more severe or uncontrolled glaucoma, BETAGAN 0.5% can be administered b.i.d. As with any new medication, careful monitoring of patients is advised. Dosages above one drop of BETAGAN 0.5% b.i.d. are not generally more effective. If the patient's IOP is not at a satisfactory level on this regimen, concomitant therapy with dipivefrin and/or epinephrine, and/or pilocarpine and other miotics, and/or systemically administered carbonic anhydrase inhibitors, such as acetazolamide, can be instituted. Patients should not typically use two or more topical ophthalmic beta-adrenergic blocking agents simultaneously.

BETAGAN^® (levobunolol hydrochloride ophthalmic solution, USP) is supplied sterile in white low density polyethylene ophthalmic dispenser bottles and tips.

BETAGAN^® 0.25% strength units include a light blue high intensity polystyrene cap.

BETAGAN^® 0.5% strength units include a yellow high intensity polystyrene cap.

BETAGAN 0.25%:

5 mL in 10 mL bottle--NDC 0023-4526-05
10 mL in 15 mL bottle--NDC 0023-4526-10

BETAGAN 0.5%:

2 mL in 5 mL bottle--NDC 0023-4385-02
5 mL in 10 mL bottle--NDC 0023-4385-05
10 mL in 15 mL bottle--NDC 0023-4385-10
15 mL in 15 mL bottle--NDC 0023-4385-15

NOTE: Protect from light. Store at 15^°-25^°C (59^°-77^°F).

Rx only

Copyright © 2004-2005 Thomson Healthcare at Montvale, NJ 07645. All rights reserved.

Bookmark this page: